BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Cedara Software Corp. (CDE) Releases Cedara I-Response(TM) Workstation Dedicated to Cancer Therapy Assessment


7/25/2007 11:11:51 AM

TORONTO, July 25 /PRNewswire-FirstCall/ -- Cedara Software, a Merge Healthcare company , and a leading medical imaging software and services company, announced the release of the Cedara I-Response application, designed to help evaluate, assess and monitor the effect of cancer therapy over time using data from multiple modalities. In addition to providing tools for the standard anatomical measurements used for tumor assessment in cancer management and research, Cedara I-Response can analyze both PET/CT and MR-based diffusion-weighted imaging (DWI). By providing the ability to visualize changes in tumors resulting from cellular and metabolic mechanisms during the course of treatment, Cedara I-Response provides clinically relevant information that potentially could be used to make mid- treatment therapy adjustments in an attempt to improve clinical outcome.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030430/MRGELOGO )

"As cancer therapies evolve and become more sophisticated, personalized treatment methods are employed, the tools needed to assess the success of those treatments must also evolve," said Cedara Software president, Loris Sartor. "I-Response addresses this challenge by offering multiple assessment methods in a single application, to accommodate the diverse needs of individual physicians in their quest to optimize treatment."

Cedara I-Response also features patented functional Diffusion Map(TM) (fDM) technology based on landmark work done at the University of Michigan. This functionality enables physicians to analyze DWI studies to visualize and quantify changes over time in the microscopic motion of water in healthy and diseased tissues. University of Michigan investigators have demonstrated that fDM can identify brain tumor patients who are responding to radiation (plus adjuvant chemotherapy in some cases) after only three weeks of treatment, more than two months earlier than conventional methods. "I-Response could provide a standardized avenue for individualized early treatment response monitoring in oncology patients," said Brian Ross, Ph.D., co-director of the molecular imaging program at the University of Michigan Comprehensive Cancer Center, and professor of radiology and biological chemistry.

The results of each analysis are included in automatically generated reports, as well as exporting the results to file for import into a site's existing data repositories. I-Response is available to OEMs as a standalone workstation, it also can be tightly integrated into existing PACS solutions using Cedara's unique C4(TM) integration platform.*

* The C4 enabled version of I-Response is a work-in-progress.

Cedara Software is a Merge Healthcare company focused on the development of customized software solutions and development tools for the medical imaging OEM market. Cedara's solutions enable OEM companies to accelerate their time-to-market, reduce development costs and access new streams of revenue. Cedara's software is deployed in hospitals and clinics worldwide and is licensed by many of the world's leading medical device and healthcare information technology companies. Cedara's technologies and engineering services span all the major digital imaging modalities and a wide variety of clinical specialties including radiology, orthopaedics, women's health, oncology, cardiac imaging, clinical trials, imaging for the veterinarian market and more. For additional information, visit our website at http://www.cedara.com.

Merge Healthcare is a leading medical imaging software and services company. Our innovative software solutions use leading-edge imaging software technologies that accelerate market delivery for our OEM customers, while our end-user solutions improve our customers' productivity and enhance the quality of patient care they provide. For additional information, visit our website at http://www.mergehealthcare.com.

All trademarks appearing in this release are the property of Cedara Software Corp. and/or Merge Healthcare.

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20030430/MRGELOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comCedara Software

CONTACT: Beth Frost-Johnson, Senior Vice President, Marketing of MergeHealthcare, +1-414-977-4000, marketing@mergehealthcare.com


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->